Login to Your Account

Elan-Wyeth Alzheimer's Trial Suspended Due to Skin Lesion

By Catherine Hollingsworth

Monday, April 21, 2008
A Phase II trial of the ACC-011 compound for Alzheimer's disease being developed by Elan Corp. plc and Wyeth Pharmaceuticals has been suspended due to a skin lesion observed in a single patient. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription